Navigation Links
DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD
Date:6/9/2009

PRINCETON, N.J., June 9 /PRNewswire-FirstCall/ -- DOR BioPharma, Inc. (DOR or the Company) (OTC Bulletin Board: DORB), a late-stage biopharmaceutical company, announced today that it has received Protocol Assistance feedback from the European Medicines Agency (EMEA) on the design of its confirmatory, pivotal, Phase 3 clinical trial evaluating its lead product orBec(R) for the treatment of acute gastrointestinal Graft-versus-Host Disease (GI GVHD).

The EMEA agreed that should the new confirmatory Phase 3 study produce positive results, the data would be sufficient to support a marketing authorization approval in all 27 European Union (EU) member states. In so doing, the EMEA agreed to the primary endpoint and the other principal design features of the new study. The EMEA's response is consistent with feedback previously received from United States Food and Drug Administration (FDA), paving the way for potential approval in the US and EU.

DOR and the FDA reached agreement on the design of the upcoming Phase 3 study via the Special Protocol Assessment (SPA) procedure. An agreement via the SPA procedure is an agreement with the FDA that a Phase 3 clinical trial's design (e.g., endpoints, sample size, control group and statistical analyses) is acceptable to support a regulatory submission seeking new drug approval.

Based on data from the prior Phase 3 study of orBec(R), the upcoming confirmatory Phase 3 clinical trial will be a highly powered, double-blind, randomized, placebo-controlled, multicenter trial and will seek to enroll an estimated 166 patients. The primary endpoint is the treatment failure rate at Study Day 80. This endpoint was successfully measured as a secondary endpoint (p-value = 0.005) in the previous Phase 3 study as a key measure of durability following a 50-day course of treatment with orBec(R) (i.e., 30 days following cessation of treatment). The confirmatory Phase 3 clinical trial wi
'/>"/>

SOURCE DOR BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
2. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
3. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
4. Plasma Products Safe Despite Swine Influenza Outbreak, Assures International Biopharmaceutical Company Octapharma
5. DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation
6. XTL Biopharmaceuticals Announces the Acquisition of the Use Patent on Recombinant Erythropoietin (rHuEPO) for the Treatment of Multiple Myeloma
7. R&D Spending by U.S. Biopharmaceutical Companies Reaches Record Levels in 2008 Despite Economic Challenges
8. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
9. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
10. Inspiration Biopharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of IB1001 for the Treatment of Hemophilia B
11. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)...  An international roster of experts on malignant pleural ... Santa Monica, Calif. , to discuss their ... a rare form of cancer that results from exposure ... of the chest. Hosted by UCLA and ... Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural ...
(Date:5/24/2013)... NEW YORK , May 24, 2013 In ... Takeover Rules and Rule 14e-1 of the United States Exchange ... levels its original offer for Elan Corporation (NYSE: ELN). ... Acquisition Limited ("Royalty Pharma") made an offer for the entire ... Elan Corporation, plc ("Elan") (the "Original Offer").  ...
(Date:5/23/2013)... 24, 2013 3SBio Inc. (NASDAQ: ... leading China -based biotechnology company ... products, announced today that, at an extraordinary general ... voted in favor of the proposal to authorize ... of merger dated February 8, 2013, among Decade ...
Breaking Medicine Technology:International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma 2International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma 3Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 2Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 3Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 4Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 5Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 6Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 7Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 8Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 93SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 23SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 3
... Presented at 2007 APA Meeting -, COLLEGEVILLE, ... four new studies examining safety and efficacy ... studied as a potential treatment for adults,with ... at the,2007 American Psychiatric Association annual meeting ...
... Childhood Condition, WASHINGTON, May 22, 2007 /PRNewswire-FirstCall/ ... pediatric patients,with gastroesophageal reflux disease (GERD) during ... Disease Week meeting held at the,Washington Convention ... support AstraZeneca's,commitment to research in the area ...
Cached Medicine Technology:New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 2New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 3New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 4New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 5New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 6New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 7New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 8New Studies Evaluating NexiumIn Pediatric GERD To Be Presented At,Annual Digestive Disease Week Meeting 2New Studies Evaluating NexiumIn Pediatric GERD To Be Presented At,Annual Digestive Disease Week Meeting 3New Studies Evaluating NexiumIn Pediatric GERD To Be Presented At,Annual Digestive Disease Week Meeting 4New Studies Evaluating NexiumIn Pediatric GERD To Be Presented At,Annual Digestive Disease Week Meeting 5
(Date:5/24/2013)... With Memorial Day Weekend upon us, cookout season has officially ... to help prevent grill fires throughout the spring and summer. ... that gas grills led to an average of 7,100 home ... meanwhile, caused approximately 1,200 home fires per year during that ... the following tips from the NFPA to help protect your ...
(Date:5/24/2013)... Calif.) (PRWEB) May 24, 2013 ... House Appropriators and the California congressional delegation, joined ... restore sequestered industry user fees paid to the ... to ensure that future across-the-board cuts will not ... of the FY14 Agriculture, Rural Development and FDA ...
(Date:5/24/2013)... 2013 Let’s face it: very few are ... for the majority of people to be uncomfortable with the ... a coffee addiction or simply genetics, yellowish or stained teeth ... popular. , Herald Square Dental is proud to ... system: Venus White Max. , Teeth become discolored for ...
(Date:5/24/2013)... The nation’s first trial of a ... da Vinci Surgical System concluded yesterday, Bernstein Liebhard LLP ... Court jury ruled in a 10-to-2 decision that Intuitive ... performed a da Vinci prostatectomy on a patient who ... alleged in their lawsuit that the da Vinci complications ...
(Date:5/24/2013)... May 24, 2013 BestSatelliteProviders.com the ... helped thousands of consumers compare the features and ... reviews site recently released the rankings of the ... are available for viewing on their website. ... , According to Adam Matthews, the spokesperson for ...
Breaking Medicine News(10 mins):Health News:Don’t Get Burned: Five Grilling Tips from Amica Insurance 2Health News:California Biomedical Industry Leaders Urge Congress to Take Action on FDA User Fees for FY2014 2Health News:California Biomedical Industry Leaders Urge Congress to Take Action on FDA User Fees for FY2014 3Health News:Herald Square Dental Introduces New In-office Whitening System: Venus White Max 2Health News:Da Vinci Robot Lawsuit News: Bernstein Liebhard LLP Comments on Verdict in Nation’s First Trial Involving Alleged Da Vinci Complications 2Health News:Da Vinci Robot Lawsuit News: Bernstein Liebhard LLP Comments on Verdict in Nation’s First Trial Involving Alleged Da Vinci Complications 3Health News:Best Rural Internet Service Provider in 2013 by BestSatelliteProviders.com 2
... ... 2008 SpeechNutrients introduced the supplement NourishLife speak™ which combines omega-3 and ... speech challenges. A recent study published in the July issue ... with verbal apraxia taking a combination of omega-3 and vitamin E ...
... ... Dysport. Dysport is the first rival for Botox. Dr. Pilest met with Medicis CEO Jonah ... who were involved in FDA trials for Dysport. , ... Irvine, CA (PRWEB) August 13, 2009 -- Dr. Nissan Pilest was ...
... , FRANKLIN LAKES, N.J. and LONDON, ... ), the world,s most advanced pharmacy(R) , today extended its ... with United Drug plc, a Pan-European healthcare leader, to provide home-based ... the country,s National Health Service (NHS). The NHS provides healthcare ...
... SILVER SPRING, Md., Aug. 12 The Association ... million in first-year funding through the President,s Emergency Plan ... laboratories and laboratory systems in participating countries. The five-year ... Centers for Disease Control and Prevention (CDC) will support ...
... survivors who lift weights are less likely than their ... arm- and hand-swelling condition that plagues many women following ... Pennsylvania School of Medicine research published in the August ... Medicine . The findings challenge the advice commonly given ...
... , , CHICAGO, Aug. 12 ... comments President Obama continues to make about the high-quality care provided by ... incorrect or not based in fact, we think he does a disservice ... facts about health care reform. We want to set the record ...
Cached Medicine News:Health News:Newly Published Research Indicates 97% of Apraxic Children Improving with Novel Nutritional Combination 2Health News:Newly Published Research Indicates 97% of Apraxic Children Improving with Novel Nutritional Combination 3Health News:Newly Published Research Indicates 97% of Apraxic Children Improving with Novel Nutritional Combination 4Health News:Orange County Derm Nissan Pilest Selected to Become Physician Trainer for Dysport 2Health News:Orange County Derm Nissan Pilest Selected to Become Physician Trainer for Dysport 3Health News:Medco Health Solutions, United Drug Announce U.K. Homecare Pharmacy Joint Venture Serving Patients with Chronic and Complex Health Conditions; Innovations to Improve Clinical Quality, Reduce Costs 2Health News:Medco Health Solutions, United Drug Announce U.K. Homecare Pharmacy Joint Venture Serving Patients with Chronic and Complex Health Conditions; Innovations to Improve Clinical Quality, Reduce Costs 3Health News:APHL Chosen by PEPFAR to Develop Global Health Laboratory Systems 2Health News:Lifting weights reduces lymphedema symptoms following breast cancer surgery, Penn research shows 2Health News:Lifting weights reduces lymphedema symptoms following breast cancer surgery, Penn research shows 3Health News:Statement from the American College of Surgeons Regarding Recent Comments from President Obama 2
... order tips. Each box contains 10,000 tips ... in easy-to-open, re-sealable Bulk Packs of 200 ... with a tamper-proof strip which can easily ... Diamond Tips. Bulk Packs are closed using ...
Capillary section fits into a 0.3-mm well for accurate loading of sequencing gels - Ideal for use with CastAway System...
This extended 10 ul combats contamination by keeping your pipettor out of 1.5 ul and 2.0 ul tubes. Utilizes MicroPoint design and 2 ul reference mark....
... powerful motor with a lightweight, comfortable design. ... three positions for maximum comfort and convenience.mum ... button on the top of the filler ... wide-angle position is ideal for restricted spaces ...
Medicine Products: